Hormonal
Semaglutide 2.4 mg weekly induces mean weight loss of ~15% and enables >20% weight loss in significant patient subsets, significantly outperforming older anti-obesity medications and lifestyle interventions alone.
Semaglutide 2.4 mg, taken once weekly, is a highly effective treatment for obesity, producing an average 15% body weight loss over 68 weeks when combined with lifestyle changes. It significantly outperforms older medications and lifestyle interventions alone, helping to overcome the biological drive to regain weight. This treatment is suitable for adults with a BMI of 30 or higher, or 27 or higher with comorbidities, and requires a gradual dose escalation to manage side effects.
Semaglutide is a newer anti-obesity medication that changes the overall landscape, as phase 3 studies show a mean weight loss near the 15% threshold and significant proportions of patients with a weight loss of greater than 20%.
Why this rating
Based on Phase 3 RCTs (STEP program) with large sample sizes and clear statistical significance.
Source
Pharmacotherapy for obesity: moving towards efficacy improvement
Walmir Coutinho et al. · Diabetology & Metabolic Syndrome · 2024
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →